HVTN 125
Status:Withdrawn
Phase:Ib
Principal Investigator(s):Susan Buchbinder & Sonya Heath
Objective:This study will evaluate the safety and immunogenicity of the IHV01 protein vaccine primed and co-administered with HIV DNA CON-S env vaccine in healthy, HIV-1-uninfected adults.Last updated January 31, 2022
Prevention Option(s):HIV Vaccine
Study Design:
Official Code:
NCT03505060
Trial Sponsors:
NIAID (DAIDS-ES: 30015)
Start Date
End Date
January 1, 2019
November 11, 2019
Enrollment:0
Age range:
18 Years ↔
50 Years
Population: